

Oncology Daily Summary

Patient Demographics

Name: Maya Hernandez

MRN: ONC-2026-0142

Date of Birth: 1978-09-12

Gender: female

Encounter

Encounter Date: 2026-02-18

Primary Oncologist: Dr. Priya Shah

Cancer Center: North Valley Cancer Center

Primary Diagnosis

Diagnosis: Metastatic breast carcinoma

Clinical Status: active

Stage: Stage IV

Body Site: left breast with liver metastases

Pathology And Biomarker Report

Report Date: 2026-02-12

Report Type: Pathology and biomarker summary

Histology: Invasive ductal carcinoma

ER: 90% positive

PR: 20% positive

HER2: IHC 1+ (HER2-low)

PD-L1: CPS 12

Conclusion: Metastatic adenocarcinoma consistent with breast primary; ER positive, HER2-low, PD-L1 CPS 12.

Recent Laboratory Results

Collection Date: 2026-02-18

Hemoglobin: 11.2 g/dL

Absolute neutrophil count: $2.4 \times 10^9/L$

Platelets: $198 \times 10^9/L$

Creatinine: 0.9 mg/dL

AST: 28 U/L

ALT: 31 U/L

CA 15-3: 48 U/mL

Active Medication List

Medication 1

Name: Capecitabine

Status: active

Dose: 1500 mg orally twice daily on days 1-14 of a 21-day cycle

Route: oral

Medication 2

Name: Ondansetron

Status: active

Dose: 8 mg every 8 hours as needed for nausea

Route: oral

Medication 3

Name: Zoledronic acid

Status: active

Dose: 4 mg every 28 days

Route: intravenous

Assessment And Plan

Current Line Of Therapy: second-line capecitabine

Treatment Response: stable symptoms, labs acceptable for treatment

Care Plan Status: active

Care Plan Intent: plan

Care Plan Description: Continue capecitabine, repeat CT chest/abdomen/pelvis in 8 weeks, and return to clinic on 2026-03-11.